DOCKET NO.: CP380D Application No.: 10/649,944

Office Action Dated: December 15, 2005

PATENT

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (currently amended) A method of treating lymphoma in a human, which comprises administering a therapeutically effective amount of one or more arsenic compounds arsenic trioxide to said human.

- 2. (canceled)
- (currently amended) The method of elaim 2 claim 1, wherein said arsenic trioxide is formulated as an ionic aqueous solution.
- 4. (original) The method of claim 1, wherein the total daily amount administered is from about 10 μg to about 200 mg.
- 5. (original) The method of claim 1, wherein the total daily amount administered is from about 0.5 mg to about 150 mg.
- 6. (original) The method of claim 1, wherein the total daily amount administered is from about 0.5 mg to about 70 mg.
- 7. (currently amended) The method of claim 1, wherein the arsenic compound <u>trioxide</u> is administered parenterally.
- 8. (currently amended) The method of claim 1, wherein the arsenic compound trioxide is administered intravenously.
- 9. (currently amended) The method of claim 1, wherein the arsenic eompound trioxide is administered in combination with an effective amount of at least one other therapeutic agent.

DOCKET NO.: CP380D PATENT

Application No.: 10/649,944

Office Action Dated: December 15, 2005

10. (original) The method of claim 9, wherein the other therapeutic agent is a chemotherapeutic or radiotherapeutic.

- 11. (original) The method of claim 9, wherein the other therapeutic agent is selected from the group consisting of etoposide, cisplatin, carboplatin, estramustine phosphate, vinblastine, methotrexate, hydroxyurea, cyclophosphamide, doxorubicin, 5-fluorouracil, taxol, diethylstilbestrol, VM-26 (vumon), BCNU, all-trans retinoic acid, procarbazine, cytokines, therapeutic vaccines, and immunomodulators.
- 12. (canceled)
- 13. (original) The method of claim 1, wherein the lymphoma is Hodgkins lymphoma.
- 14. (original) The method of claim 1, wherein the lymphoma is non-Hodgkin's lymphoma.
- 15. (original) The method of claim 1, wherein the lymphoma is follicular lymphoma.
- 16. (original) The method of claim I, wherein the lymphoma is diffuse lymphoma.
- 17. (original) The method of claim 1, wherein the lymphoma is lymphoblastic lymphoma.
- 18. (canceled).
- 19. (original) The method of claim 1, wherein the lymphoma is small lymphocytic lymphoma.
- 20. (original) The method of claim 1, wherein the lymphoma is HIV-related non-Hodgkin's lymphoma.